SURVYR

TLX

Telix Pharmaceuticals Limited
$10.08
−$1.08 (9.68%)Oct 21 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-42%-26%-10%+6%+22%Oct 2025Oct 2026Apr 202652w high $13.1152w low $6.28
TLXSPY
Wall St. Highest PT $22.11 (+119.4%) Wall St. Avg PT $20.52 (+103.5%)
$6$11$15$19$23POC $11Hi $22Avg $21
Underwater Drawdown %Max DD -41.5%Current -21.4%
0.0%-41.5%
Relative Strength vs SPY-23.0% vs SPYUnderperforming
+50%0%-50%
1W
−$0.57 (5.35%)
1M
−$1.23 (10.88%)
3M
−$0.24 (2.33%)
6M
−$0.25 (2.42%)
YTD
+$2.59 (34.58%)
1Y
−$0.84 (7.69%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
5 analysts · mean score 1.00
1 = Strong Buy · 5 = Sell
Strong Buy00%
Buy5100%
Hold00%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$10.08
Average target$20.52
+$10.44 (+103.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$18.03
Median$20.96
High$22.11
12-month Wall Street target range
Recent analyst rating changes · 27
Reiterated
2026-10-21 · Wedbush reiterated Outperform on TLX
Reiterated
2026-09-25 · HC Wainwright & Co. reiterated Buy on TLX
Reiterated
2026-09-23 · Wedbush reiterated Outperform on TLX
Reiterated
2026-09-15 · HC Wainwright & Co. reiterated Buy on TLX
Reiterated
2026-09-14 · Wedbush reiterated Outperform on TLX
Reiterated
2026-09-02 · HC Wainwright & Co. reiterated Buy on TLX
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$3.1B
P/E (last 12 months)91.5
P/E (next 12 months, estimated)-371.9
52-week range$6.28 – $13.11
Revenue growth (latest quarter vs a year ago)+22.3%
Dividend yieldNo dividend
Analyst consensusStrong Buy (4)
Average analyst price target$20.52 (+104%)

What they do

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC).

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for TLX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

TLX earningsNo upcoming date on file
Source: Yahoo Finance · refreshed 2026-10-25 17:23:21 ET
No EPS history available.

News & catalysts

More news
TLX, Ekalia Team Up to Boost US Production of Isotope for Cancer Therapies
MT Newswires · Oct 19
Rating changes
Reiterated
2026-10-21 · Wedbush reiterated Outperform on TLX
Reiterated
2026-09-25 · HC Wainwright & Co. reiterated Buy on TLX
Reiterated
2026-09-23 · Wedbush reiterated Outperform on TLX
Reiterated
2026-09-15 · HC Wainwright & Co. reiterated Buy on TLX
Reiterated
2026-09-14 · Wedbush reiterated Outperform on TLX
Reiterated
2026-09-02 · HC Wainwright & Co. reiterated Buy on TLX

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-25 17:23:21 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026